A detailed history of Cowen And Company, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Cowen And Company, LLC holds 161,186 shares of SAGE stock, worth $876,851. This represents 0.03% of its overall portfolio holdings.

Number of Shares
161,186
Previous 214,232 24.76%
Holding current value
$876,851
Previous $2.33 Million 50.04%
% of portfolio
0.03%
Previous 0.06%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$7.02 - $13.08 $372,382 - $693,841
-53,046 Reduced 24.76%
161,186 $1.16 Million
Q2 2024

Aug 07, 2024

SELL
$10.58 - $17.9 $2.32 Million - $3.92 Million
-218,846 Reduced 50.53%
214,232 $2.33 Million
Q1 2024

May 03, 2024

SELL
$18.62 - $26.95 $16.9 Million - $24.4 Million
-906,893 Reduced 67.68%
433,078 $8.12 Million
Q4 2023

Feb 12, 2024

BUY
$17.1 - $22.26 $22.9 Million - $29.8 Million
1,339,971 New
1,339,971 $29 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.